CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Novostia aims to revolutionize heart valve replacements with the TRIFLO valve, designed for durability and to prevent blood clotting. This innovative solution addresses the needs of younger patients suffering from valvular heart disease.
Novostia is a medical device company with the mission to provide young patients suffering from heart disease with a solution for life: the TRIFLO valve.
Valvular heart disease affects more than 100 million people worldwide.
Every year >500.000 patients undergo a heart valve replacement.
For patients younger than 65 years, currently available valves have serious constraints: either blood clot formation requiring lifelong dangerous anticoagulation therapy (with mechanical valves), or deterioration…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
